Back to List View Graph View

Tirzepatide

Tirzepatide is a synthetic peptide drug, given as a once-weekly subcutaneous injection, approved for the treatment of type 2 diabetes and obesity and marketed under the brand names Mounjaro and Zepbound (developed as LY3298176).

Where the papers sit

39 papers from the last 6 months study tirzepatide directly · updated from PubMed 16 Nov 2026

  • Tirzepatide Metabolic Outcomes

    Tirzepatide is being tested across type 1 and type 2 diabetes, obesity, older adults, youth, and patients without obesity. Recurrent endpoints are weight loss, hemoglobin A1c, body composition, hypoglycemia, liver fat, and broader cardiometabolic risk. Real-world comparisons with semaglutide, bariatric surgery, and emerging combination therapies are replacing narrow efficacy claims. Low-dose strategies, persistence, tolerability, and treatment access remain important limitations.

    19 papers · 48.7%

  • GLP-1 Therapy in Obesity

    GLP-1 and dual GIP/GLP-1 therapies are moving from trial evidence into real-world obesity and diabetes care. Tirzepatide and semaglutide are being evaluated for weight loss, post-bariatric weight regain, glycaemic control, treatment persistence, and access. Safety surveillance increasingly complements effectiveness studies, including adverse-event reporting and treatment-related outcomes. Financing, adherence, and appropriate patient selection remain unresolved as use broadens.

    15 papers · 38.5%

  • Obesity and Sleep Apnea

    Weight-loss treatment is increasingly being linked to improvements in obstructive sleep apnea symptoms and objective disease measures. Tirzepatide and GLP-1 receptor agonists are also being assessed for cardiovascular and pulmonary risks in patients with obesity, sleep apnea, and type 2 diabetes. Rare gastrointestinal complications such as pneumatosis intestinalis highlight the need for safety surveillance alongside efficacy. The evidence remains focused on clinical benefit and complication recognition rather than a settled treatment pathway.

    3 papers · 7.7%

  • Metabolic Liver Disease

    Metabolic dysfunction-associated steatohepatitis with fibrosis is being framed within interconnected cardiovascular, kidney, and metabolic disease. Semaglutide and resmetirom appear alongside broader pharmacologic strategies for reducing steatosis and fibrosis. Cost-effectiveness is becoming a central question as treatment options expand. The field is moving toward integrated risk assessment rather than liver-only management.

    2 papers · 5.1%

PARADIGM SHIFT

Clinically meaningful tirzepatide outcomes may not require escalation beyond 5 mg weekly

The low-dose obesity cohort comparing 2.5 mg with 5 mg and the older-adult type 2 diabetes cohort restricted to a maximum dose of 5 mg both found that low-dose tirzepatide produced substantial clinical benefit without evidence that routine escalation was necessary: 2.5 mg and 5 mg achieved similar six-month weight outcomes, while most older adults maintained treatment and met glycaemic or weight-loss targets on doses no higher than 5 mg. This challenges the assumption that higher maintenance doses are required for useful efficacy and supports dose-sparing treatment strategies, particularly when tolerability or treatment simplicity is important 42521631Jul 42880590Oct.

NEW DIRECTION

Tirzepatide is repurposed as a dual-target PET imaging agent

The radiolabeled tirzepatide-derivative study in INS-1 and A549-GIPR xenograft models assigns tirzepatide a role outside the set’s therapeutic uses: structural modification converted it into a PET probe for visualizing GLP-1R/GIPR distribution, tirzepatide biodistribution, and neuroendocrine tumors. This changes tirzepatide from a drug studied for metabolic treatment into an imaging platform, although excessive non-target uptake remains an optimization problem. 42969740Nov

Papers

The 39 papers from the last 6 months that study tirzepatide directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.

By theme

Tirzepatide Metabolic Outcomes (19)
  1. Clinical Feasibility of a Low-Dose Tirzepatide Strategy in Older Adults with Type 2 Diabetes: Persistence, Metabolic Benefit, and Treatment Simplification in a Real-World Cohort. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 15 Oct 2026 PMID 42880590
  2. Real-world treatment patterns and cost per patient achieving treatment targets among tirzepatide and semaglutide initiators in US patients with type 2 diabetes. Journal of managed care & specialty pharmacy · 29 Sept 2026 PMID 42808550
  3. Real-world effectiveness of 6-month tirzepatide therapy on body weight and composition in adults with overweight and obesity. Journal of diabetes and its complications · 28 Sept 2026 PMID 42805130
  4. Peer Referral Pathways and 6-Month Outcomes in a Tirzepatide-Supported Digital Weight Loss Service: Retrospective Cohort Study. Journal of medical Internet research · 28 Sept 2026 PMID 42804756
  5. Real-World Evidence for Existing Anti-Obesity Therapies-The Realities of Treatment Adherence, Tolerability, Access and Patient Satisfaction. Diabetes, obesity & metabolism · 15 Sept 2026 PMID 42736522
  6. Increased energy expenditure through intermittent cold exposure does not enhance tirzepatide-induced weight loss in obese mice. American journal of physiology. Regulatory, integrative and comparative physiology · 10 Sept 2026 PMID 42722006
  7. Major Adverse Liver Outcomes With Tirzepatide and Injectable Semaglutide in Adults With Overweight or Obesity and Type 2 Diabetes. Obesity (Silver Spring, Md.) · 19 Aug 2026 PMID 42618523
  8. Achieving the triple endpoint of body weight reduction thresholds, systolic blood pressure reduction ≥5 mmHg and non-HDL cholesterol <130 mg/dL with tirzepatide in people with obesity: A post hoc analysis from the SURMOUNT trials. PloS one · 13 Aug 2026 PMID 42594122
  9. Liver Fat Changes in Patients With Type 2 Diabetes by Presence of Genetic Hepatic Steatosis: A Post Hoc Analysis of SURPASS-3 MRI. Liver international : official journal of the International Association for the Study of the Liver · 11 Aug 2026 PMID 42576670
  10. Real-world effectiveness of tirzepatide among youth with type 2 diabetes and/or obesity: a multicenter analysis. Journal of pediatric endocrinology & metabolism : JPEM · 11 Aug 2026 PMID 42576608
  11. Tirzepatide and the risk of atherosclerotic cardiovascular events: population based cohort study. BMJ (Clinical research ed.) · 5 Aug 2026 PMID 42556854
  12. Concurrent initiation of tirzepatide and biologics improves patient-reported outcomes in obese psoriatic arthritis: a propensity score-matched study. RMD open · 30 Jul 2026 PMID 42532547
  13. Low-Dose Tirzepatide for Obesity: Comparative Efficacy of 2.5 mg Versus 5 mg in Non-Diabetic Japanese Adults. Diabetes, obesity & metabolism · 28 Jul 2026 PMID 42521631
  14. Real-world clinical outcomes of tirzepatide administration in older patients with type 2 diabetes, with a focus on the risk of hypoglycemia and weight loss-related parameters. Endocrine journal · 15 Jul 2026 PMID 42457543
  15. Real-World Effectiveness and Safety of Tirzepatide in Type 1 Diabetes and Obesity: Impact on Glycaemia, Weight, and Cardiometabolic Risk Markers. Diabetes, obesity & metabolism · 6 Jul 2026 PMID 42410316
  16. Tirzepatide Is Associated With Improved Metabolic Outcomes in People With Type 1 Diabetes and Overweight or Obesity: A Retrospective Cohort Study. Diabetes, obesity & metabolism · 2 Jul 2026 PMID 42387290
  17. 1-year outcomes of semaglutide, tirzepatide, and sleeve gastrectomy in obesity in type 2 diabetes: a retrospective cohort study. The lancet. Diabetes & endocrinology · 17 Jun 2026 PMID 42309121
  18. Effectiveness of tirzepatide in Japanese patients with type 2 diabetes but no obesity: A sub-analysis of Hokkaido-TZP study data. Journal of diabetes investigation · 15 Jun 2026 PMID 42289805
  19. Comparative Effectiveness of CagriSegma, Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta-Analysis of Randomized Clinical Trials. Endocrinology, diabetes & metabolism · 28 May 2026 PMID 42207966
GLP-1 Therapy in Obesity (15)
  1. Real-world effectiveness of tirzepatide in individuals with obesity: weight response, treatment-related factors and diabetes status. Diabetes & metabolism · 12 Nov 2026 PMID 43020464
  2. PET Imaging of Dual GLP-1R and GIPR Targeting with [18F]AlF-NOTA-Asp2-Tirzepatide. Molecular pharmaceutics · 2 Nov 2026 PMID 42969740
  3. Comparative adverse-event reporting patterns of semaglutide and tirzepatide: a disproportionality analysis of FAERS. Endocrine · 29 Oct 2026 PMID 42955519
  4. Characteristics and Treatment Utilisation Patterns of Individuals Using Tirzepatide for Type 2 Diabetes in Germany. Advances in therapy · 26 Oct 2026 PMID 42928086
  5. Tirzepatide safety in EudraVigilance: descriptive and disproportionality analysis of preferred terms related to suboptimal treatment outcomes and drug-use-related issues. BMJ open · 1 Oct 2026 PMID 42823110
  6. GLP-1 Receptor Agonists Post-Bariatric Surgery (GRABS) Trial: Rationale, Design and Baseline Characteristics. Diabetes, obesity & metabolism · 9 Sept 2026 PMID 42712125
  7. Changes in recorded background glucose-lowering therapy after initiation of a GLP-1 receptor agonist or dual GIP/GLP-1 receptor agonist in adults with type 2 diabetes. Diabetes research and clinical practice · 10 Aug 2026 PMID 42575344
  8. Real-World Effectiveness and Treatment Patterns of Tirzepatide in a Large UK Digital Health Cohort. Diabetes, obesity & metabolism · 6 Aug 2026 PMID 42560020
  9. Association between GLP-1 receptor agonists and alcohol-related hospitalisations among adults with alcohol use disorder: multi-target trial emulation study. BMJ open · 21 Jul 2026 PMID 42481079
  10. Preventative semaglutide and tirzepatide treatment does not alter disease progression in the 5xFAD mouse model of Alzheimer's disease. Cell reports. Medicine · 7 Jul 2026 PMID 42413499
  11. Real-World Effectiveness of Semaglutide and Tirzepatide Compared With Bariatric Surgery. Obesity (Silver Spring, Md.) · 25 Jun 2026 PMID 42345739
  12. Real-world and computational identification of herbal candidates associated with adverse event patterns in glucagon-like peptide-1 therapy for obesity. Scientific reports · 12 Jun 2026 PMID 42286047
  13. GLP-1 receptor agonist adjunct therapy stabilises Ramadan dysglycaemia in insulin-treated diabetes: a CGM-based study. Diabetes research and clinical practice · 10 Jun 2026 PMID 42269776
  14. Tirzepatide for Recurrent Weight Gain after Bariatric Procedures: Real-World Evidence of Efficacy and Safety. Obesity surgery · 5 Jun 2026 PMID 42247124
  15. ICER report demonstrates both the value and challenges in financing of weight loss medications. Journal of managed care & specialty pharmacy · 21 May 2026 PMID 42166309
Obesity and Sleep Apnea (3)
  1. Tirzepatide-induced pneumatosis intestinalis: a rare but clinically significant gastrointestinal adverse effect. American journal of clinical pathology · 10 Oct 2026 PMID 42857919
  2. Changes in patient-reported outcomes and objective assessments based on baseline symptom severity in SURMOUNT-OSA: post-hoc analyses. Sleep · 7 Jul 2026 PMID 42412744
  3. GLP-1 receptor agonists and Risk of Cardiovascular and Pulmonary Complications in patients with OSA and Type 2 Diabetes Mellitus. Sleep & breathing = Schlaf & Atmung · 27 Jun 2026 PMID 42363996
Metabolic Liver Disease (2)
  1. Integrating the liver into the cardiovascular-kidney-metabolic syndrome: pathophysiology and therapeutic implications. Current opinion in nephrology and hypertension · 2 Sept 2026 PMID 42683763
  2. Cost-Effectiveness of Pharmacologic Therapies for Metabolic Dysfunction-Associated Steatohepatitis With Significant Fibrosis in the United States. Diabetes, obesity & metabolism · 25 Jun 2026 PMID 42348222

By study type

Clinical trials (4)
  1. GLP-1 Receptor Agonists Post-Bariatric Surgery (GRABS) Trial: Rationale, Design and Baseline Characteristics. Diabetes, obesity & metabolism · 9 Sept 2026 PMID 42712125
  2. Achieving the triple endpoint of body weight reduction thresholds, systolic blood pressure reduction ≥5 mmHg and non-HDL cholesterol <130 mg/dL with tirzepatide in people with obesity: A post hoc analysis from the SURMOUNT trials. PloS one · 13 Aug 2026 PMID 42594122
  3. Liver Fat Changes in Patients With Type 2 Diabetes by Presence of Genetic Hepatic Steatosis: A Post Hoc Analysis of SURPASS-3 MRI. Liver international : official journal of the International Association for the Study of the Liver · 11 Aug 2026 PMID 42576670
  4. Changes in patient-reported outcomes and objective assessments based on baseline symptom severity in SURMOUNT-OSA: post-hoc analyses. Sleep · 7 Jul 2026 PMID 42412744
Observational studies and case reports (13)
  1. Comparative adverse-event reporting patterns of semaglutide and tirzepatide: a disproportionality analysis of FAERS. Endocrine · 29 Oct 2026 PMID 42955519
  2. Tirzepatide-induced pneumatosis intestinalis: a rare but clinically significant gastrointestinal adverse effect. American journal of clinical pathology · 10 Oct 2026 PMID 42857919
  3. Tirzepatide safety in EudraVigilance: descriptive and disproportionality analysis of preferred terms related to suboptimal treatment outcomes and drug-use-related issues. BMJ open · 1 Oct 2026 PMID 42823110
  4. Real-world treatment patterns and cost per patient achieving treatment targets among tirzepatide and semaglutide initiators in US patients with type 2 diabetes. Journal of managed care & specialty pharmacy · 29 Sept 2026 PMID 42808550
  5. Real-world effectiveness of 6-month tirzepatide therapy on body weight and composition in adults with overweight and obesity. Journal of diabetes and its complications · 28 Sept 2026 PMID 42805130
  6. Peer Referral Pathways and 6-Month Outcomes in a Tirzepatide-Supported Digital Weight Loss Service: Retrospective Cohort Study. Journal of medical Internet research · 28 Sept 2026 PMID 42804756
  7. Major Adverse Liver Outcomes With Tirzepatide and Injectable Semaglutide in Adults With Overweight or Obesity and Type 2 Diabetes. Obesity (Silver Spring, Md.) · 19 Aug 2026 PMID 42618523
  8. Real-world effectiveness of tirzepatide among youth with type 2 diabetes and/or obesity: a multicenter analysis. Journal of pediatric endocrinology & metabolism : JPEM · 11 Aug 2026 PMID 42576608
  9. Changes in recorded background glucose-lowering therapy after initiation of a GLP-1 receptor agonist or dual GIP/GLP-1 receptor agonist in adults with type 2 diabetes. Diabetes research and clinical practice · 10 Aug 2026 PMID 42575344
  10. Tirzepatide and the risk of atherosclerotic cardiovascular events: population based cohort study. BMJ (Clinical research ed.) · 5 Aug 2026 PMID 42556854
  11. Concurrent initiation of tirzepatide and biologics improves patient-reported outcomes in obese psoriatic arthritis: a propensity score-matched study. RMD open · 30 Jul 2026 PMID 42532547
  12. 1-year outcomes of semaglutide, tirzepatide, and sleeve gastrectomy in obesity in type 2 diabetes: a retrospective cohort study. The lancet. Diabetes & endocrinology · 17 Jun 2026 PMID 42309121
  13. Effectiveness of tirzepatide in Japanese patients with type 2 diabetes but no obesity: A sub-analysis of Hokkaido-TZP study data. Journal of diabetes investigation · 15 Jun 2026 PMID 42289805
Human data, design not indexed (7)
  1. Association between GLP-1 receptor agonists and alcohol-related hospitalisations among adults with alcohol use disorder: multi-target trial emulation study. BMJ open · 21 Jul 2026 PMID 42481079
  2. Real-world clinical outcomes of tirzepatide administration in older patients with type 2 diabetes, with a focus on the risk of hypoglycemia and weight loss-related parameters. Endocrine journal · 15 Jul 2026 PMID 42457543
  3. GLP-1 receptor agonists and Risk of Cardiovascular and Pulmonary Complications in patients with OSA and Type 2 Diabetes Mellitus. Sleep & breathing = Schlaf & Atmung · 27 Jun 2026 PMID 42363996
  4. Real-World Effectiveness of Semaglutide and Tirzepatide Compared With Bariatric Surgery. Obesity (Silver Spring, Md.) · 25 Jun 2026 PMID 42345739
  5. GLP-1 receptor agonist adjunct therapy stabilises Ramadan dysglycaemia in insulin-treated diabetes: a CGM-based study. Diabetes research and clinical practice · 10 Jun 2026 PMID 42269776
  6. Comparative Effectiveness of CagriSegma, Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta-Analysis of Randomized Clinical Trials. Endocrinology, diabetes & metabolism · 28 May 2026 PMID 42207966
  7. ICER report demonstrates both the value and challenges in financing of weight loss medications. Journal of managed care & specialty pharmacy · 21 May 2026 PMID 42166309
Preclinical: animal, cell and lab studies (3)
  1. PET Imaging of Dual GLP-1R and GIPR Targeting with [18F]AlF-NOTA-Asp2-Tirzepatide. Molecular pharmaceutics · 2 Nov 2026 PMID 42969740
  2. Increased energy expenditure through intermittent cold exposure does not enhance tirzepatide-induced weight loss in obese mice. American journal of physiology. Regulatory, integrative and comparative physiology · 10 Sept 2026 PMID 42722006
  3. Preventative semaglutide and tirzepatide treatment does not alter disease progression in the 5xFAD mouse model of Alzheimer's disease. Cell reports. Medicine · 7 Jul 2026 PMID 42413499
Unclassified: not yet indexed with MeSH (12)
  1. Real-world effectiveness of tirzepatide in individuals with obesity: weight response, treatment-related factors and diabetes status. Diabetes & metabolism · 12 Nov 2026 PMID 43020464
  2. Characteristics and Treatment Utilisation Patterns of Individuals Using Tirzepatide for Type 2 Diabetes in Germany. Advances in therapy · 26 Oct 2026 PMID 42928086
  3. Clinical Feasibility of a Low-Dose Tirzepatide Strategy in Older Adults with Type 2 Diabetes: Persistence, Metabolic Benefit, and Treatment Simplification in a Real-World Cohort. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 15 Oct 2026 PMID 42880590
  4. Real-World Evidence for Existing Anti-Obesity Therapies-The Realities of Treatment Adherence, Tolerability, Access and Patient Satisfaction. Diabetes, obesity & metabolism · 15 Sept 2026 PMID 42736522
  5. Integrating the liver into the cardiovascular-kidney-metabolic syndrome: pathophysiology and therapeutic implications. Current opinion in nephrology and hypertension · 2 Sept 2026 PMID 42683763
  6. Real-World Effectiveness and Treatment Patterns of Tirzepatide in a Large UK Digital Health Cohort. Diabetes, obesity & metabolism · 6 Aug 2026 PMID 42560020
  7. Low-Dose Tirzepatide for Obesity: Comparative Efficacy of 2.5 mg Versus 5 mg in Non-Diabetic Japanese Adults. Diabetes, obesity & metabolism · 28 Jul 2026 PMID 42521631
  8. Real-World Effectiveness and Safety of Tirzepatide in Type 1 Diabetes and Obesity: Impact on Glycaemia, Weight, and Cardiometabolic Risk Markers. Diabetes, obesity & metabolism · 6 Jul 2026 PMID 42410316
  9. Tirzepatide Is Associated With Improved Metabolic Outcomes in People With Type 1 Diabetes and Overweight or Obesity: A Retrospective Cohort Study. Diabetes, obesity & metabolism · 2 Jul 2026 PMID 42387290
  10. Cost-Effectiveness of Pharmacologic Therapies for Metabolic Dysfunction-Associated Steatohepatitis With Significant Fibrosis in the United States. Diabetes, obesity & metabolism · 25 Jun 2026 PMID 42348222
  11. Real-world and computational identification of herbal candidates associated with adverse event patterns in glucagon-like peptide-1 therapy for obesity. Scientific reports · 12 Jun 2026 PMID 42286047
  12. Tirzepatide for Recurrent Weight Gain after Bariatric Procedures: Real-World Evidence of Efficacy and Safety. Obesity surgery · 5 Jun 2026 PMID 42247124